Shots:

• The P-I/II study involves assessing Mobocertinib (160mg- PO) in patients with EGFR Exon20 insertion+ mNSCLC who received prior Pt-based CT
• The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over 1yr of follow up and will be presented at the ASCO. The updated results demonstrated an encouraging ORR (28%)- DoR (17.5mos.)- OS (24mos.)- DCR (78%)
• Mobocertinib has received the US FDA’s BTD in Apr’2020 and PR for NDA in Apr’2021. If approved- mobocertinib will be the first oral therapy available that is specifically designed to selectively target EGFR Exon20 insertion mutations

  Ref: Takeda | Image: Takeda